The Effect of Photobiomodulation on Microvascular Blood Flow: The Role of Wavelength and Skin Temperature

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-31

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to assess peripheral microcirculatory hemodynamic responses to photobiomodulation in participants with normal circulation and with functional peripheral vasoconstriction, using noninvasive thermography, photoplethysmography, and laser Doppler flowmetry.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Peripheral Microcirculation Hemodynamics Following Various Changes Based on Noninvasive Thermography

NCT03357523

Microcirculation

COMPLETED NA

Microvascular Blood Flow During Passive Heating

NCT06565221

Blood Flow

NOT_YET_RECRUITING NA

Circulation and Oxygenation Changes of Deep Tissue Respond on LLLT

NCT04936165

Low Level Light/Laser Therapy Near Infrared Spectroscopy

UNKNOWN NA

Evaluating the State of Microvessels by Minimum Rise Time (MRT01)

NCT02527070

Healthy

COMPLETED NA

Acute Effects of Leg Heating on Skeletal Muscle Blood Flow

NCT03763357

Peripheral Arterial Disease

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a within-subject experimental study in which each participant completes two study sessions. Microvascular and systemic variables are continuously monitored in response to photobiomodulation delivered at either a blue or near-infrared wavelength, with each wavelength applied in a separate session.

Each session includes a baseline period with controlled breathing, followed by photobiomodulation and a 20-minute post-intervention follow-up period. Peripheral microcirculatory responses are assessed using noninvasive thermography, photoplethysmography, and laser Doppler flowmetry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microcirculation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This is a within-subject crossover study in which participants receive photobiomodulation at blue and near-infrared wavelengths in separate sessions, with the order of exposure assigned in a crossover manner. Participants may present with functional peripheral vasoconstriction or normal peripheral temperature at baseline; these baseline characteristics will be used for subgroup analyses and do not define separate study arms.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blue → Near-Infrared PBM

Participants receive photobiomodulation at a blue wavelength in the first session and at a near-infrared wavelength in the second session.

Group Type EXPERIMENTAL

Photobiomodulation - Blue Wavelength

Intervention Type DEVICE

Photobiomodulation delivered at a blue wavelength (400-500 nm) to the hands during a single study session as part of a randomized crossover design.

Photobiomodulation - Near Infrared

Intervention Type DEVICE

Photobiomodulation delivered at a near-infrared wavelength (780-1100 nm) to the hands during a single study session as part of a randomized crossover design.

Near-Infrared → Blue PBM

Participants receive photobiomodulation at a near-infrared wavelength in the first session and at a blue wavelength in the second session.

Group Type EXPERIMENTAL

Photobiomodulation - Blue Wavelength

Intervention Type DEVICE

Photobiomodulation delivered at a blue wavelength (400-500 nm) to the hands during a single study session as part of a randomized crossover design.

Photobiomodulation - Near Infrared

Intervention Type DEVICE

Photobiomodulation delivered at a near-infrared wavelength (780-1100 nm) to the hands during a single study session as part of a randomized crossover design.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Photobiomodulation - Blue Wavelength

Photobiomodulation delivered at a blue wavelength (400-500 nm) to the hands during a single study session as part of a randomized crossover design.

Intervention Type DEVICE

Photobiomodulation - Near Infrared

Photobiomodulation delivered at a near-infrared wavelength (780-1100 nm) to the hands during a single study session as part of a randomized crossover design.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy males and females, between 20 and 75 years of age.
2. Willing to sign informed consent.
3. Willing to participate in two separate sessions, one for each wavelength.
4. Able to avoid caffeine and alcohol for at least 3 hours before each session.
5. Able to sit comfortably with both hands at heart level for the full measurement duration.

Exclusion Criteria

1. Currently smoking
2. Any abnormal skin condition in the area of light irradiation.
3. Pregnant, having given birth less than 3 months ago, and/or breastfeeding.
4. History of photosensitive conditions or use of photosensitizing medications
5. Suffering from significant concurrent illness, such as cardiac disorders or pertinent neurological disorders.
6. As per the Investigator's discretion, any physical or mental condition that might make it unsafe for the subject to participate in this study.

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes